7. Sarepta Therapeutics Inc. (NASDAQ: SRPT)
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) ranks seventh among the best cheap biotech stocks to buy now, even as the company navigates a period of mixed analyst sentiment following its most recent earnings report. Sarepta is widely known in the biotechnology industry for its work in RNA-targeted therapies and gene therapy treatments aimed at rare genetic disorders, particularly Duchenne muscular dystrophy.
Despite some cautious adjustments to price targets from analysts, the broader outlook for Sarepta remains constructive. Wells Fargo lowered its price target to $38 from $45 while maintaining an Overweight rating, noting that the launch trajectory of ELEVIDYS gene therapy may take longer to stabilize following safety-related concerns. However, the firm continues to expect favorable outcomes from upcoming siRNA clinical data.
Financially, Sarepta delivered substantial revenue in 2025. Net product revenue for the year totaled $1.864 billion, including nearly $966 million from PMO therapies and roughly $899 million from ELEVIDYS gene therapy. Fourth-quarter revenue reached $369.6 million, demonstrating the continued commercial strength of the company’s treatment portfolio.
For investors seeking cheap biotech stocks with exposure to cutting-edge gene therapy technologies, Sarepta remains a company closely watched by both analysts and institutional investors.
Click next to see the following stock...
